Zacks Investment Research Lowers Deciphera Pharmaceuticals (DCPH) to Hold

Zacks Investment Research cut shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a buy rating to a hold rating in a report released on Monday.

According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “

Other research analysts have also recently issued reports about the company. Nomura began coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a buy rating and a $57.00 price target on the stock. Piper Jaffray Companies began coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an overweight rating and a $35.00 price target on the stock. BidaskClub upgraded Deciphera Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, January 3rd. JMP Securities began coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set an outperform rating and a $38.00 price target on the stock. Finally, Instinet began coverage on Deciphera Pharmaceuticals in a research note on Monday, October 23rd. They set a buy rating and a $57.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and a consensus target price of $40.83.

Deciphera Pharmaceuticals (NASDAQ:DCPH) traded up $0.59 on Monday, reaching $25.66. The company had a trading volume of 134,500 shares, compared to its average volume of 185,686. Deciphera Pharmaceuticals has a 12-month low of $15.15 and a 12-month high of $26.59. The firm has a market capitalization of $815.93 and a PE ratio of -6.48.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($5.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($5.30). equities research analysts expect that Deciphera Pharmaceuticals will post -2.91 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in Deciphera Pharmaceuticals during the third quarter worth $143,000. FNY Managed Accounts LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the third quarter valued at $153,000. Pura Vida Investments LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the third quarter valued at $1,329,000. Sphera Funds Management LTD. purchased a new position in Deciphera Pharmaceuticals in the third quarter valued at $1,424,000. Finally, Perceptive Advisors LLC purchased a new position in Deciphera Pharmaceuticals in the third quarter valued at $1,946,000. Institutional investors own 43.94% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2018/01/11/zacks-investment-research-lowers-deciphera-pharmaceuticals-dcph-to-hold.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Get a free copy of the Zacks research report on Deciphera Pharmaceuticals (DCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply